Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE: TOL-3021 in Type 1 Diabetes Mellitus
NCT03895437Phase 2Terminated
- Sponsor
- Tolerion
- Start
- Jun 2019
- Primary completion
- Dec 2020
- Modality
- Prophylactic Vaccines, Gene Editing, Gene Silencing
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in type 1 diabetes mellitus (T1D) comparing TOL-3021 with TOL-3021 Placebo (2 arms). Primary endpoint: Change From Baseline on Log-transformed Mixed Meal Tolerance Test (MMTT) C-peptide Area Under the Curve (AUC) at 24 weeks. Started Jun 2019; status: terminated.
02
Drugs
TOL-3021
03
Conditions
type 1 diabetes mellitus (T1D)
Beyond the preview
Go deeper on NCT03895437.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03895437.